From Lab Dish to Patient: The Long Road in Biotech

Scientists sometimes discover something in a laboratory that could change medicine forever. But turning that discovery into a real drug or treatment that reaches patients is a very different challenge. It can take many years, cost enormous sums of money, and require passing test after test. Understanding how hard that journey is matters just as much as understanding the science itself.

Imagine a small company — let's call it XYZ Bio — whose scientists found a molecule they think could fight an aggressive cancer. The lab results look exciting, and investors start imagining big profits. But XYZ Bio doesn't have a medicine yet. What it has is a promising idea, and between that idea and the first sale sits one of the toughest obstacle courses in business.

Before any drug can reach a patient, it must pass through several major stages. First comes laboratory research, where scientists test their idea in dishes and animal models. Then comes pre-clinical testing, which checks things like safety and dosing. Only after that can human trials begin, and every stage costs more than the last.

A treatment that works perfectly in a lab dish or an animal might behave very differently inside a human body. That gap between lab results and human results is one of the earliest and trickiest hurdles. NeuroScientific Biopharmaceuticals is currently working through this stage, building evidence needed to move its StemSmart product for Crohn's disease toward human trials. It is set to meet with the FDA at the end of August to review its development plan.

Another Australian company, Argenica Therapeutics, has already crossed that divide. Its drug ARG-007 is designed to protect brain cells, and after extensive pre-clinical work it moved into a first human safety study. It has now progressed into Phase II testing in stroke patients. The questions being asked change at each new phase.

In Phase I trials, researchers mainly ask: is this treatment safe for humans? In Phase II, they start looking at whether it actually works, while still watching for safety problems. In Phase III, the treatment is tested on a much larger group of people to gather the strong evidence regulators need before approving it for sale. Each phase is bigger, more complex, and more expensive than the one before.

Investors often cheer when a biotech announces positive trial results, but it is important to ask the right questions. Was the trial large enough? Did it meet its main goal? A small, encouraging result and a large, well-controlled study are very different things, even if both sound exciting in a press release. Reading carefully matters.

Amplia Therapeutics is a strong example of solid clinical evidence. It is testing a drug called narmafotinib against pancreatic cancer, and in a study of 64 patients, 35.9 percent showed a major reduction in tumor size. Five patients even saw their cancer disappear completely, which is extremely rare. Median overall survival was 11.1 months — about 30 percent better than chemotherapy alone.

While trials are running, a quiet but critical question is being worked out behind the scenes: who is going to manufacture the medicine? Manufacturing has to be developed alongside the clinical program, not after it. As a product moves closer to market, the rules about how it is made become much stricter. Every batch must be produced the same way, to the same quality, every single time — a standard known as Good Manufacturing Practice, or GMP.

Perth-based Syngenis specialises in making synthetic DNA and RNA molecules called oligonucleotides, used in treatments, diagnostic tests, and research. It is building its manufacturing capability toward clinical-grade production, meaning it could help supply material for multiple drug programs. Rather than depending on just one drug's success, Syngenis aims to participate across many development programs.

Not every biotech follows the same road to market. Vaccines go through a similar process, but because they are given to millions of healthy people, safety requirements are especially strict. Diagnostic tests — tools that detect disease — follow a different path, where developers must prove their test is accurate using two key numbers: how well it finds people who have a condition, and how well it avoids wrongly flagging people who don't.

Perth-based Proteomics International is working through that process with its Promarker platform, which uses proteins in the blood to diagnose diseases like diabetic kidney disease and endometriosis. Its PromarkerD test has already reached commercialisation, and PromarkerEndo has secured US patent protection and is moving toward being ready for sale. Even after a test is proven accurate, getting hospitals and doctors to use it is yet another challenge.

Medical devices and health software take yet another path. Perth company Singular Health makes 3DICOM, a technology that turns regular medical scans into detailed three-dimensional images. Its desktop version received US FDA clearance in 2022, and a cloud-based version followed in early 2025. There were no traditional drug trials because the regulatory process for devices is based on the risks the device poses.

Cell therapies and gene therapies are among the most complex technologies of all. These treatments work by modifying cells or introducing genetic material to fight disease. Arovella Therapeutics is working with a cell therapy designed to target cancer, and just getting ready to treat the first patient requires manufacturing approvals, ethics clearances, and fully prepared clinical sites. It is itself a major development exercise.

Once a company gets regulatory approval, the work is still not over. Orthocell's nerve-repair product, Remplir, received US FDA clearance in April 2025, and since then the company has been setting up manufacturing, warehousing, and distribution in the United States. It has also been connecting with surgeons who will use the product. Getting a green light from regulators opens a door — but a company still has to walk through it.

Even after years of research and regulatory work, XYZ Bio would face one final question: can it actually build a market? Doctors must prescribe the drug, health systems must agree to pay for it, and patients must benefit from it. Investors sometimes forget this step and get excited too early. The smarter questions are less thrilling but far more useful — what has been proven, what will it cost to get further, and who will ultimately pay?